Nintedanib ethanesulfonate salt 656247-18-6

$50.00

≥1 Gram

Min. Order:: 1 Gram

Min. Order:: 1 Gram

Transportation:: Ocean, Air, Express

Port:: Shanghai, Hangzhou

Quantity:

Your message must be between 20 to 2000 characters

Contact Now

Basic Info

Payment Type:	L/C,T/T,D/A,Paypal
Incoterm:	FOB,CIF
Transportation:	Ocean,Air,Express
Port:	Shanghai,Hangzhou

Product Description

Product name	Nintedanib Ethanesulfonate Salt
CAS NO.	656247-18-6
Appearance	white powder
Category	Pharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals.
Standard	purity:>99%
Shelf life	2 years

Nintedanib Introduction

Nintedanib is the first FDA-approved drug for the management of idiopathic pulmonary fibrosis (IPF), a rare but often fatal lung disease. Nintedanib is believed to exert its mechanism of action by inhibiting multiple receptor tyrosine kinases, including those that have been implicated in the pathogenesis of IPF (i.e., fibroblast growth factor receptor, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor). Nintedanib also inhibits nonreceptor tyrosine kinases, although the contribution of this inhibition in the efficacy of the drug is unknown.

Function

Nintedanib BIBF (1120) is a kind of indole moiety ketone derivative oral activity of triple kinase inhibitor, on the vascular endothelial growth factor receptor (VEGFR1/2/3), fibroblast growth factor receptor (FGFR1/2/3) and platelet-derived growth factor receptor (PDGFR alpha/beta) has inhibitory effect, in the Moore (IC50, 20-100 nmol/L) of scope by blocking these receptor mediated signal pathway, with effective anti-angiogenesis activity . Nintedanib (BIBF 1120) can be used in clinical studies in the treatment of idiopathic pulmonary fibrosis because these receptors may be involved in the pathogenesis of pulmonary fibrinolysis [3,4]. As a novel angiogenic inhibitor, Nintedanib has also been widely evaluated in various cancer models, and it exerts significant anti-tumor activity by inhibiting tumor angiogenesis

COA

Item	Specification	Results
Appearance	White Powder	White Powder
Assay	99.0%--101.0%(Anhydrous substance)	99.98%
Purity	≥99.0%	99.89%
Water	≤1.0%	0.1%
Sulphated ash	≤0.5%	0.045%
Related substances	Unspecified impurities for each impurity	Complies
Heavy Metals	≤10ppm	<10ppm
Loss On Drying	≤2.0%	0.19%

Send your message to this supplier

* From:
* To:

Ms. Lily
* Messages:

Enter between 20 to 4,000 characters.

Related Keywords

Nintedanib Ethanesulfonate Salt , 656247-18-6 , API